These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 17130431)
1. Blockade of chemokine signaling in patients with multiple sclerosis. Zipp F; Hartung HP; Hillert J; Schimrigk S; Trebst C; Stangel M; Infante-Duarte C; Jakobs P; Wolf C; Sandbrink R; Pohl C; Filippi M; Neurology; 2006 Nov; 67(10):1880-3. PubMed ID: 17130431 [TBL] [Abstract][Full Text] [Related]
2. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Polman C; Barkhof F; Sandberg-Wollheim M; Linde A; Nordle O; Nederman T; Neurology; 2005 Mar; 64(6):987-91. PubMed ID: 15781813 [TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ; Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164 [TBL] [Abstract][Full Text] [Related]
4. No significant effect of orally administered chemokine receptor 1 antagonist on intercellular adhesion molecule-3 expression in relapsing--remitting multiple sclerosis patients. Reuss R; Schreiber V; Klein A; Infante-Duarte C; Filippi M; Pabst W; Pohl C; Oschmann P Mult Scler; 2010 Mar; 16(3):366-9. PubMed ID: 20086017 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320 [TBL] [Abstract][Full Text] [Related]
6. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Krapf H; Morrissey SP; Zenker O; Zwingers T; Gonsette R; Hartung HP; Neurology; 2005 Sep; 65(5):690-5. PubMed ID: 16157900 [TBL] [Abstract][Full Text] [Related]
7. Chemokine receptor CCR1: a new target for progressive kidney disease. Ninichuk V; Anders HJ Am J Nephrol; 2005; 25(4):365-72. PubMed ID: 16088077 [TBL] [Abstract][Full Text] [Related]
8. [Blockade of chemokines in chronic inflammatory diseases]. Haringman JJ; Tak PP Ned Tijdschr Geneeskd; 2004 Sep; 148(36):1760-4. PubMed ID: 15495938 [TBL] [Abstract][Full Text] [Related]